European MS Platform

@emspofficial.bsky.social

Advocacy and expertise for over 1 million people living with #MultipleSclerosis and related disorders in Europe.

🧬 New insights into EBV and multiple sclerosis (MS) EBV-MS researchers found that MS is linked to stronger EBV-specific immune responses, reduced by anti-CD20 therapy. The findings support future EBV-targeted vaccines and antiviral approaches. Read the paper: buff.ly/LOEmoR0

CD4+ T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis

CD4+ T cells in MS preferentially recognize EBV viral particles rather than latent antigens, and responses are reduced by B cell–targeting therapies.

buff.ly

Welcome to the team, Delphine Sartiaux — our new Fundraising & Development Manager! Delphine brings rich experience in fundraising, strategic partnerships & international stakeholder engagement across global health NGOs. Delighted to have her on board 👋

Bild

Progress on a new MS therapy — shaped by the people it's for. At IMMUTOL's 3rd Annual Meeting in Siena 🇮🇹, EMSP brought expert patients Rebecca Maguire & Anna Revilla into the room as the consortium advanced its vitamin D3 dendritic cell therapy for MS. 🧠

Bild